Stoekenbroek RM - Search Results

1

Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study.

Stoekenbroek RM, Boekholdt SM, Luben R, Hovingh GK, Zwinderman AH, Wareham NJ, Khaw KT, Peters RJ. Stoekenbroek RM, et al. Eur Heart J. 2016 Mar 14;37(11):880-9. doi: 10.1093/eurheartj/ehv630. Epub 2015 Dec 17. Eur Heart J. 2016. PMID: 26681771

2

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.

Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Stoekenbroek RM, et al. Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16. Heart. 2015. PMID: 25595417 Clinical Trial.

3

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.

Verbeek R, Boekholdt SM, Stoekenbroek RM, Hovingh GK, Witztum JL, Wareham NJ, Sandhu MS, Khaw KT, Tsimikas S. Verbeek R, et al. Among authors: stoekenbroek rm. J Lipid Res. 2016 Apr;57(4):697-705. doi: 10.1194/jlr.P066258. Epub 2016 Jan 31. J Lipid Res. 2016. PMID: 26828068 Free PMC article.

4

Can we afford not to screen for FH?

Stoekenbroek RM, Kastelein JJP, Hovingh GK. Stoekenbroek RM, et al. Eur Heart J. 2017 Jun 14;38(23):1840-1842. doi: 10.1093/eurheartj/ehx197. Eur Heart J. 2017. PMID: 28444214 No abstract available.

5

Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs.

Stoekenbroek RM, Kastelein JJ, Hovingh GK. Stoekenbroek RM, et al. Curr Opin Lipidol. 2013 Dec;24(6):459-66. doi: 10.1097/MOL.0000000000000024. Curr Opin Lipidol. 2013. PMID: 24184941 Review.

6

PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.

Verbeek R, Stoekenbroek RM, Hovingh GK. Verbeek R, et al. Among authors: stoekenbroek rm. Eur J Pharmacol. 2015 Sep 15;763(Pt A):38-47. doi: 10.1016/j.ejphar.2015.03.099. Epub 2015 May 16. Eur J Pharmacol. 2015. PMID: 25989132 Review.

7

New Drugs for Atherosclerosis.

Bruikman CS, Stoekenbroek RM, Hovingh GK, Kastelein JP. Bruikman CS, et al. Among authors: stoekenbroek rm. Can J Cardiol. 2017 Mar;33(3):350-357. doi: 10.1016/j.cjca.2016.09.010. Epub 2016 Oct 17. Can J Cardiol. 2017. PMID: 27993452 Review.

8

ApoA-I mimetics.

Stoekenbroek RM, Stroes ES, Hovingh GK. Stoekenbroek RM, et al. Handb Exp Pharmacol. 2015;224:631-48. doi: 10.1007/978-3-319-09665-0_21. Handb Exp Pharmacol. 2015. PMID: 25523005 Review.

9

Inhibiting PCSK9 - biology beyond LDL control.

Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Stoekenbroek RM, et al. Nat Rev Endocrinol. 2018 Dec;15(1):52-62. doi: 10.1038/s41574-018-0110-5. Nat Rev Endocrinol. 2018. PMID: 30367179 Review.

10

PCSK9 inhibitors in clinical practice: Delivering on the promise?

Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK. Stoekenbroek RM, et al. Atherosclerosis. 2018 Mar;270:205-210. doi: 10.1016/j.atherosclerosis.2017.11.027. Epub 2017 Dec 1. Atherosclerosis. 2018. PMID: 29254691 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page